Selank research: studies, doses and safety

A Russian nasal anxiety peptide with uncertain long-term benefit and safety.

Also called: Селанк, TP-7, Tuftsin-PGP, TKPRPGP.

Nootropic peptides · Tuftsin-derived peptide studied for anxiety and cognition.

A human anxiety study used Selank for 14 days while measuring immune markers; this does not establish a long-term treatment course.

20 human reports may include repeated participants. People often knew which treatment they received; lasting benefit and safety remain unclear.

Key studies

  • Generalized anxiety and neurasthenia: A small active-comparator trial does not prove equivalence. (source)
  • Immune markers during anxiety care: Blood-marker changes do not show protection from infections. (source)
  • Selank versus phenazepam: Less sedation, but a smaller day-14 anxiety-score reduction. (source)
  • Adding Selank to phenazepam: The day-14 responder comparison was not statistically significant. (source)
  • Early phase 2 congress report: A selected sample was studied in a conference report. (source)
  • Rapid versus gradual response: Response groups were defined after treatment without a placebo control. (source)

Related to Selank

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.